Last reviewed · How we verify
ARSI
ARSI is an androgen receptor signaling inhibitor that blocks androgen receptor activity to suppress hormone-dependent cancer cell growth.
ARSI is an androgen receptor signaling inhibitor that blocks androgen receptor activity to suppress hormone-dependent cancer cell growth. Used for Castration-resistant prostate cancer, Androgen receptor-driven malignancies.
At a glance
| Generic name | ARSI |
|---|---|
| Sponsor | City of Hope Medical Center |
| Drug class | Androgen receptor inhibitor |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ARSI targets the androgen receptor pathway, which is critical for the growth and survival of androgen-dependent malignancies such as prostate cancer. By inhibiting androgen receptor signaling, the drug aims to prevent cancer cell proliferation and induce apoptosis in hormone-sensitive tumors. This mechanism is particularly relevant in castration-resistant prostate cancer and other AR-driven malignancies.
Approved indications
- Castration-resistant prostate cancer
- Androgen receptor-driven malignancies
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
Key clinical trials
- PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
- Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial (PHASE2)
- Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer (PHASE1)
- Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer (PHASE2)
- Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R) (PHASE2)
- Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (PHASE2)
- Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer (PHASE3)
- ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |